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Background: Porous hydroxyapatite/collagen composite (HAp/Col) is a bioresorbable bone substitute
composed of nano-scale HAp and porcine type 1 collagen. In this study, the efﬁcacy and safety were
assessed in comparison to commercially available porous b-tricalcium phosphate (b-TCP).
Methods: Patients with bone defects caused by benign bone tumors, fractures, or harvesting of autografts
were randomly allocated for implantation of porous HAp/Col (n ¼ 63) or porous b-TCP (n ¼ 63). X-ray
images were scored and used to evaluate the efﬁcacy of the implantation until 24 weeks after surgery.
Blood tests and observation of the surgical site were also performed to evaluate the safety of the im-
plants. In total, 59 and 60 cases were analyzed in the porous HAp/Col and b-TCP groups, respectively.
Results: At 18 and 24 weeks after surgery, the highest grade of bone regeneration was more frequent in
the porous HAp/Col group than in the porous b-TCP group (p ¼ 0.0004 and 0.0254 respectively). Wil-
coxon's rank sum test conﬁrmed the superiority of porous HAp/Col from early time points onward
(p ¼ 0.0084, 4 w; p ¼ 0.0037, 8 w; p ¼ 0.0030, 12 w; p < 0.0001, 18 w; and p ¼ 0.0316, 24 w). The
incidence of adverse effects was higher in the porous HAp/Col group than in the b-TCP group. However,
no serious adverse events were reported and no cases needed to drop out of the clinical trial.
Conclusions: The superiority of porous HAp/Col for bone regeneration in comparison to an established
porous b-TCP was conﬁrmed. Although the incidence of side effects associated with the porous HAp/Col
implant was higher than that in the b-TCP group, no serious adverse events occurred that resulted in
rejection of the implants.
© 2016 The Authors. Published by Elsevier B.V. on behalf of The Japanese Orthopaedic Association.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).).
B.V. on behalf of The Japanese Ort1. Introduction
In the ﬁeld of orthopedic surgery, bone grafting is generally used
to accelerate the healing of bone defects, especially in the case of
relatively large defects. Autologous bone grafts are the gold stan-
dard because of their osteogenic capability and mechanical prop-
erties. However, it is well known that harvesting of autografts ishopaedic Association. This is an open access article under the CC BY-NC-ND license
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alternatives to autografts and are free from the donor sitemorbidity
that occurs with use of autografts. However, the osteogenic capa-
bility depends on the donor and processing method, and the risk of
disease transmission cannot be completely eliminated [3,4].
Therefore, a demand exists for substitute materials, and various
types of bone substitutes have been developed including sintered
calcium phosphate, injectable calcium phosphate, demineralized
bone matrix, and mineralized naturally derived polymers [3,4].
Hydroxyapatite/collagen composite (HAp/Col) that is synthe-
sized by reacting porcine type 1 atelocollagen dissolved in H3PO4
solution with a Ca(OH)2 suspension to obtain a coprecipitate is a
recently developed material for bone substitutes. HAp/Col is
composed of collagen ﬁbers and HAp nanocrystals deposited on
the ﬁbers, and the nano-structure resembles that of natural bone5.
The porous body of HAp/Col is formed through ice crystal forma-
tion, and the collagen ﬁbers are cross-linked by thermal dehy-
dration at 140 C, which is far lower than the standard HAp
sintering temperature. Therefore, the HAp nanocrystals do not
bond to each other, and the resulting surface area is very large [6].
Previous studies using animal models conﬁrmed the high osteo-
conductivity and bio-resorbability of HAp/Col [7,8]; furthermore,
although the porosity of HAp/Col reduces its mechanical strength,
the resulting sponge-like elasticity provides superb handling
during surgery [9].
This clinical trial was conducted to evaluate the efﬁcacy and
safety of porous HAp/Col as a bone void ﬁller in comparison with
commercially available porous b-tricalcium phosphate (TCP), which
is the current clinical standard in Japan [10,11].
2. Materials and methods
A multicenter, unblinded, randomized controlled, phase 3,
clinical trial of porous HAp/Col (Reﬁt®; HOYA Technosurgical Co.,
Tokyo, Japan) in comparison with a commercially available porous
b-tricalcium phosphate bone substitute (Osferion®; Olympus Co,
Tokyo, Japan) was conducted at six institutes. The porous HAp/Col
was provided by HOYA Technosurgical Co., and porous b-TCP was
purchased from Olympus Co. The study was approved by the
institutional review board of each institution and conducted in
conformity with Japanese good clinical practice (GCP) for medical
devices.
2.1. Study design
From September 2006 to July 2010, 130 patients who required
bone substitute implantation into bone defects smaller than
30 cm3 caused by a benign bone tumor, fracture, or harvesting of a
bone autograft were enrolled in this study. The number of cases
was determined according to the following pro forma calculation:
Prior to this clinical trial, a non-clinical animal study using a canine
model that compared porous HAp/Col with porous b-TCP had been
conducted. The proportion of cases evaluated as having undergone
highly efﬁcient regeneration, i.e., complete bone regeneration and
complete resorption of the implant, in the porous b-TCP and
porous HAp/Col groups was 40% and 80%, respectively (unpub-
lished data). From this previous non-clinical trial and previous
reports, and based on an assumption of reduced efﬁcacy under
actual clinical conditions, the proportion of cases with highly
efﬁcient regeneration at 24 weeks in the porous b-TCP group in the
present study was predicted to be 10e40%, and the proportion of
cases with highly efﬁcient regeneration in the porous HAp/Col
group was predicted to be 25e40% higher than that in the porous
b-TCP group. Based on the 70% one-sided conﬁdence limit for the
proportion of highly efﬁcient cases in the previous non-clinicalstudy, the required number of cases in each group to detect su-
periority of the porous HAp/Col was calculated with a signiﬁcance
level of 0.05 and a power level of 0.80. The maximum case number
(62 cases in each group) was the number calculated to be required
to detect superiority of porous HAp/Col with a proportion of highly
efﬁcient responses of 65% in the porous HAp/Col group and 40% in
the porous b-TCP group. The exclusion criteria are described in
Table 1. Patients were registered at a registration center indepen-
dent from the medical institutes and the manufacturers of the
implants and allocated to the porous HAp/Col group or porous b-
TCP group using a computer-based minimization method to match
the cause of the bone defect, age of the patients, volume of the
bone defect, and institute where the surgery was performed.
Because the implants were easily distinguished by the surgeons,
blinding was not considered and the surgeons were not prohibited
from informing the patients of which implant was implanted.
There were no notable changes in the protocol after the trial
commenced. After the allocation, two patients from each group
were excluded because three patients refused to participate in this
study and one patient was found to meet the exclusion criteria.
Then, in each group, 63 patients underwent implanted surgery.
However, four patients from the HAp/Col group and three patients
from the b-TCP group were excluded from the following analyses
because of inappropriate interventions applied during the study
(Fig. 1). The porous HAp/Col used in the study was in a block format
(10  10  10 mm or 30  20  10 mm, porosity: 95%, macropore
size: 100e500 mm), whereas the porous b-TCP was in block
(10  10  10 mm or 30  20  10 mm, porosity: 75%, macropore
size: 100e400 mm) and granular formats (granule sizes were
0.1e1.5, 1.0e3.0, 2.3e5.0, or 4.7e8.0 mm). Immediately prior to
implantation, the porous HAp/Col was wetted by blood in the
operative ﬁeld or from other sites, or by normal saline, to soften the
implants. In the b-TCP group, block-form implants were generally
used except when the surgeons judged that the gaps between the
block-form implants and the recipient bone were large enough to
inhibit osteoconduction or the volume of the defects was too small
to use the block-form implants.
2.2. Assessment of efﬁcacy
To evaluate the efﬁcacy of the implants, X-ray images were
taken prior to and peri-surgery, and at 2, 4, 8, 12, 18, and 24 weeks
after surgery. According to scoring criteria deﬁned based on
continuity with the surrounding tissue and bone regeneration
and remodeling at the implantation site (Table 2), the images
were scored by three raters independent from the trial in-
stitutions who were all orthopedic surgeons and experts in this
ﬁeld. Although no information regarding implant group assign-
ment was given to the raters, they easily identiﬁed the implant
material in each site because b-TCP was easily identiﬁed in X-ray
images, whereas porous HAp/Col was hardly detectable. In each
case, the score was assigned by majority rule, and when agree-
ment could not be reached, the score was decided by discussion.
On a scale of four points, cases that scored four points, three
points, two points, and one to zero points were assessed as highly
effective, effective, less effective, and ineffective, respectively.
Computed tomography images were also taken in cases with an
implantation volume greater than 10 cm3 and used as references
for scoring.
2.3. Safety assessment
Because both types of implant are biodegradable through
resorption by osteoclasts, the effects of implantation on the pa-
tients was assessed. To assess the systemic effects of implantation,
Table 1
Inclusion and exclusion criteria.
Inclusion criteria
Patients with bone defects caused by benign tumors, fractures, or harvesting of
autografts
The volume of the bone defect was within 30 cm3.Patients whose general
condition was sufﬁciently stable for surgery
Patients who provided ﬁrst-person informed consent
Patients over 20 years old
Patients who would be able to undergo scheduled examinations
Exclusion criteria
Patients administered the following drugs within three months prior to
implantation:
steroids or other immunosuppressants
bisphosphonates
selective estrogen receptor modulators
immunosuppressive agents
Patients diagnosed with the following disorders:
osteomyelitis, malignant tumor,
severe diabetes, chronic kidney failure,
abnormal hormonal metabolism, or calcium metabolism
Patients with allergic responses to:
collagen, gelatin, hydroxyapatite, or b-tricalcium phosphate
Pregnant women
Patients with pathological fractures except for those caused by osteoporosis
Patients with transplantation sites with severe vascular insufﬁciency or
neurological disorders
S. Sotome et al. / Journal of Orthopaedic Science 21 (2016) 373e380 375the blood and urine were tested before surgery, immediately after
surgery, and 2, 4, 8, 12, 18 and 24 weeks after surgery. The local
response at the implantation site was evaluated by observing the
state of the operative wound.Fig. 1. CONSORT diagram showing th2.4. Statistical analysis
The proportion of cases assessed as highly effective, i.e., with
complete regeneration, at each time point was compared between
the groups using the Mantel-Haenszel statistic. Wilcoxon's rank
sum test was used to determine which implant achieved a higher
efﬁcacy score at each time point. In both analyses, stratiﬁed com-
parisons were performed to adjust for implanted volume.
3. Results
3.1. Assessment of efﬁcacy
The data for the enrolled patients, implanted volume, and
speciﬁcations of the implants are described in Table 3, and the lo-
cations of the bone defects are described in Table 4. Average im-
plantation volume of the HAp/Col group and b-TCP group were
3.64 cm3 and 3.77 cm3 respectively. Except for patient sex as
analyzed by Fisher's exact test (p ¼ 0.108), the backgrounds of the
patients and implanted volume were well matched between the
groups. In the b-TCP group, to ﬁll bone defects of various shapes,
granular implants were used alone or together with block-format
implants in 42 cases, and the block-format implants were cut to
adjust to the defect shape in only 13 cases. In contrast to the b-TCP
group, in 36 cases in the porous HAp/Col group, the implants were
cut into the desired shape using a surgical knife or scissors because
the sponge-like elasticity of the porous HAp/Col enabled superb
handling and easy cutting (Fig. 2).
The progression of the factorial estimations and the overall ef-
ﬁcacy scores over time as determined from x-ray images were
shown in Figs. 3 and 4 respectively, and the scores at 24 weekse ﬂow of patients in the study.
Table 2
Scoring criteria for assessing efﬁcacy of the implants using X-ray images.
Evaluation Score
Evaluation of marginal zone (Osteointegration, radiolucent line) 2 All-around osteointegration
1 Partial osteointegration
0 All-around radiolucent line
Bone regeneration (Degradation and replacement of the implant) 2 Complete replacement by regenerated bone
1 Partial replacement by regenerated bone
0 No bone regeneration or no degradation of implants
Total score
4 Highly effective
3 Effective
2 Less effective
1 or 0 Ineffective
Table 3
Data for the enrolled patients, implanted volume, and speciﬁcations of the implants.
P e HAp/Col P e b-TCP
Sex (male/female) 28/31 36/24
Age (years)
59 & 28 25
40 & 59 25 27
20 & 39 6 8
Mean (SD) 43.2 (13.4) 43.2 (14.8)
Bone defect caused by
Bone tumor 46 48
Fracture 3 2
Harvesting of autograft 10 10
Implantation volume (cm3)
3 38 36
3 & 10 15 17
10 & 30 cm3 6 7
Mean (SD) 3.64 (5.43) 3.87 (5.17)
Type Size
Block 10  10  10 mm 52 17
30  20  10 mm 7 6
Granule 0.1e1.5 mm e 4
1.0e3.0 mm e 22
2.3e5.0 mm e 10
4.7e8.0 mm e 6
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an implanted volume greater than 10 cm3, after the scores were
determined based on x-ray images, CT images were secondarily
used to validate the scores. Although the scores improved over time
during the follow-up period in both groups, the scores in the HAp/
Col group increased earlier. At 18 weeks after surgery, 44.7% of theTable 4
Location of bone defect.
P e HAp/Col P e b-TCP
Scaplula, clavicle, ribs 3 2
Upper extremity 31 27
Humerus 2 1
Ulna 5 1
Radius 4 4
Carpal bones 2 1
Metacarpal bones, phalanges of hand 18 20
Ilium 5 9
Lower extremity 20 22
Femur 2 5
Patella 2 1
Tibia 4 5
Fibula 1 2
Calcaneus, talus 3 1
Metatarsal bones, phalanges of foot 8 8HAp/Col cases achieved remarkable efﬁcacy (i.e., complete regen-
eration), whereas only 13.9% of the b-TCP cases showed remarkable
efﬁcacy. However, most cases in both groups were assessed as
effective or better (HAp/Col: 94.7%, b-TCP: 83.3%) at 24 weeks after
surgery, which was the last follow-up time point of the study.
At each time point, the proportion of the cases assessed as
highly effective was compared using the Mantel-Haenszel statistic
(Table 5). At 18 and 24 weeks, the proportion of highly effective
cases was signiﬁcantly higher in the HAp/Col group than in the b-
TCP group (p ¼ 0.0004 and p ¼ 0.0254, respectively). Stratiﬁed
Wilcoxon's rank sum test performed at each time point indicated
superiority of the porous HAp/Col from early time points onward,
with p¼ 0.0084 at 4 weeks, p¼ 0.0037 at 8 weeks, p¼ 0.0030 at 12
weeks, p < 0.0001 at 18 weeks, and p ¼ 0.0316 at 24 weeks. The
effects of sex, age, and defect size on efﬁcacywere also analyzed but
determined to not be statistically signiﬁcant.3.2. Safety assessment
Adverse events that had the possibility of being associated with
the implants were assessed as side effects of the implantation. The
side effects that occurred in both groups are shown in Table 6.
Although 18 cases among the 59 HAp/Col cases (30.5%) presented
side effects, the side effects in 15 of these cases subsided without
any treatment, whereas in three cases considered to be associated
with infection, the side effects subsided upon antibiotic adminis-
tration. Side effects were also observed in two cases in the b-TCP
group (3.4%); one case resolved without treatment, and the other
required antibiotic administration. Thus, the side effects in either
group were not sufﬁciently severe to cause cases to drop out from
the study. In the HAp/Col group, 2 cases indicated transient mild
increase of bilirubin although the preoperative bilirubin value had
also been increased in one of the cases. In two cases of the HAp/Col
group, AST, ALT and g-GTP were increased. In one of the cases
(implant volume: 0.3 cm3), the preoperative basal values of the
patient had already been increased and the increase persisted at
constant levels throughout the study period except for at two
weeks after the surgery when the value increased transiently. In the
other case (implant volume: 1 cm3), exhibited transient mild in-
creases around two weeks of the implantation. Four cases of the
HAp/Col group exhibited mild increase of WBC after surgery.
However, the value returned to normal level within a fewweeks. In
ﬁve cases of the HAp/Col group, CRP exhibited increase after sur-
gery and then returned to a normal level in the same manner as
WBC. All the WBC or CRP increased cases were also included in the
cases of wound swelling, rubor, increased effusion or infection. The
infection case of the b-TCP group exhibited increase of WBC and
CRP four weeks after the implantation, and the value returned to
normal level within a few weeks. Two patients in HAp/Col group
Fig. 2. Sponge-like elasticity of wet porous HAp/Col provides superior handling during surgery and facilitates cutting with a surgical knife or scissors.
Fig. 3. The score of marginal zone was scored based on continuity with the sur-
rounding tissue and the score of bone regeneration was scored based on bone
regeneration and remodeling at the implant site.
Fig. 4. Results of x-ray evaluation. The scores improved over time during the follow-up
period in both groups. At each time point, the score in the HAp/Col group was higher
than that in the b-TCP group.
Fig. 5. Results of x-ray evaluation at the end point of the study. The case numbers
assigned to each grade are presented and classiﬁed according to the implanted volume.
Table 5
Proportion of cases assessed as highly effective.
% Of highly effective 95% Conﬁdence interval P -value
12 w P e HAp/Col 10.3 3.9e21.2
0.2980P e b-TCP 5.0 1.0e13.9
18 w P e HAp/Col 42.4 29.6e55.9
0.0004P e b-TCP 13.3 5.9e24.6
24 w P e HAp/Col 66.1 52.6e77.9
0.0254P e b-TCP 45.0 32.1e58.4
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vance with wound swelling, rubor or effusion.3.3. Case reports
Case 1: Implantation into an autograft harvest site (female, 59
years of age) (Fig. 6).
An autograft containing cortical bone was harvested from the
ulnar to provide a strut bone graft for necrotic lunate. Porous HAp/
Col (2 cm3) was then implanted into the harvesting site. At 24
weeks after surgery, although obvious bone regeneration was
observed, the shape of bone at the harvest site sagged compared to
the original shape. Also in other cases whose implants were
exposed to extraskeletal tissue due to the lack of cortical bone like
the case 1, the regenerated bone sagged to some extent at the
exposed aspects regardless of the implant. An efﬁcacy score of 3
Table 6
Adverse events possibly associated with the implants.
Side effects P e HAp/Col P e b-TCP
Number % Number %
Abnormal value of ALP 1 1.7 0 0.0
AST, ALT, or gGTP 2 3.4 0 0.0
Bilirubin 2 3.4 0 0.0
Total protein 1 1.7 0 0.0
Ca 1 1.7 0 0.0
P 3 5.1 1 1.7
WBC 4 6.8 1 1.7
CRP 5 8.5 1 1.7
Detection of urine protein 1 1.7 0 0.0
Contracture of joints 1 1.7 0 0.0
Fracture 0 0.0 1 1.7
Local warmth 1 1.7 0 0.0
Wound swelling, rubor, increased effusion 6 10.2 0 0.0
Whitish effusion 2 3.4 0 0.0
Infection of the implant site 2 3.4 1 1.7
Pain 2 3.4 0 0.0
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(marginal zone) þ 1 (bone regeneration) ¼ 3 (total)].
Case 2: Implantation into a bone defect caused by a benign tu-
mor (male, 41 years of age) (Fig. 7).
Porous HAp/Col (1.75 cm3) was implanted into a bone defect
caused by enchondroma of the proximal phalanx of the thumb.
Immediately after surgery, thinning of the cortical bone and
disappearance of the trabecular bone was observed. At 24 weeks
after implantation, recovery of cortical bone thickness and trabec-
ular structure was conﬁrmed. The ﬁnal efﬁcacy score was 4 and the
regeneration was classiﬁed as highly effective [(2 (marginal
zone) þ 2 (bone regeneration) ¼ 4 (total)].
Case 3: Implantation into a bone defect caused by a benign tu-
mor (Female, 33 years of age) (Fig. 8).
Porous HAp/Col (8 cm3) was implanted after the resection and
curettage of a benign tumor of the patella. Bone regeneration at the
implant site progressed with time. Although the osteosclerotic wall
formed by the tumor remained, adequate bone regeneration at the
defect was conﬁrmed at 24 weeks after surgery. The ﬁnal efﬁcacy
score was 4 and the regeneration was classiﬁed as highly effective
[2 (marginal zone) þ 2 (bone regeneration) ¼ 4 (total)].Fig. 6. Case 1: Implantation into an autograft harvest site. Porous HAp/Col (2 cm3) was impla
study (24 weeks) was 3 and the regeneration was classiﬁed as effective.4. Discussion
HAp/Col is composed of nano-scale hydroxyapatite (80 w/w %)
and porcine skin-derived atelocollagen (20 w/w %), and its nano-
structure resembles that of natural bone [5]. The porous body of
HAp/Col, once wetted, becomes elastic like a sponge and is thus
easy to implant into bone defects of various shapes. Animal studies
have shown vigorous bone formation at sites implanted with
porous HAp/Col together with bio-resorbability of the implants
[7,8]. In the present study, a multicenter randomized controlled
trial was conducted to conﬁrm the clinical efﬁcacy and safety of the
porous HAp/Col. In this study, commercially available porous b-TCP
was used as the control implant because it is one of the most
popular bio-resorbable bone void ﬁller materials in Japan and thus
represents a clinical standard [10,11]. The efﬁcacy scores for bone
regeneration and implant resorption for porous HAp/Col increased
earlier than those of porous b-TCP and thus demonstrated the su-
periority of porous HAp/Col. Regarding safety, although adverse
events occurred more frequently in the HAp/Col group, serious
adverse events did not occur and no cases dropped out.
Recently, micro-porous structures in which cells cannot migrate
have been emphasized because of the importance of such struc-
tures for biomaterial osteoinductivity and osteoconductivity
[12,13]. One of the key functions of the micro-pores is to increase
the bioactive surface area of the material, thereby enhancing its
ability to engage in biological reactions that mediate osteogenesis.
The porous b-TCP used as the control in this study has a micro-
porous structure with superior osteoconductivity compared to
the former generation of porous HAp [11] but also limited
osteoinductivity [14]. The porous HAp/Col evaluated clinically for
the ﬁrst time in this study also has a micro-porous structure, and
the micro-pores and HAp nano-crystals of the porous HAp/Col give
rise to a large surface area of approximately 70e80 m2/g [6]. This
increased bioactive area is thus considered to underlie the superior
osteoconductivity of HAp/Col.
The elasticity of the porous HAp/Col is considered to be another
factor contributing to the superiority of HAp/Col for bone regen-
eration and remodeling. Our unpublished previous study using
porous HAp/Col and block-format porous b-TCP identiﬁed a dif-
ference in the osteoconduction of the implants, where gaps be-
tween the recipient bone and the implanted b-TCP block werented into an autograft harvest site in the ulna. The efﬁcacy score at the end point of the
Fig. 7. Case 2: Implantation into a bone defect caused by enchondroma. Porous HAp/Col (1.75 cm3) was implanted into a bone defect in the proximal phalanx of the thumb. The ﬁnal
efﬁcacy score was 4 and the regeneration was classiﬁed as highly effective.
Fig. 8. Case 3: Implantation into a bone defect caused by a benign tumor. Porous HAp/Col (8 cm3) was implanted into a bone defect in the patella. Although the osteosclerotic wall
remained, the ﬁnal efﬁcacy score was 4 and the regeneration was classiﬁed as highly effective.
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the host bone skipped these gaps, and ﬁbrous tissue formed be-
tween the host bone and the bone that formed inside the implant.
This ﬁnding corresponded with the results of a previous study that
reported a radiolucent zone between the implanted porous b-TCP
and the surrounding bone [11,15]. In the present study, in contrast
to the b-TCP blocks, the implanted porous HAp/Col conformed to
the shape of the bone defect without gaps, and the bone con-
duction directly progressed continuously from the host bone into
the implant. Therefore, the elasticity of porous HAp/Col contrib-
utes not only to handling during surgery but also to early bone
regeneration.We used x-ray images to score the bone regeneration and
remodeling. Porous HAp/Col is scarcely detectable by x-ray
immediately after implantation because of its high porosity [8].
Therefore, once bone formation occurs, the newly formed bone is
easily detected by x-ray, and the actual bone formation should
correlate well with the x-ray ﬁndings. In contrast to porous HAp/
Col, because b-TCP is radiopaque, it was difﬁcult to detect early
bone formation inside or around the b-TCP implants. Moreover,
the resorption of b-TCP was slower than that of porous HAp/Col
because of its lower porosity. Based on these aspects, the scoring
system used in the present study may have been somewhat biased
against b-TCP, especially during the early phase. In fact, the efﬁ-
cacy score of the HAp/Col group at 4 weeks was higher than that
S. Sotome et al. / Journal of Orthopaedic Science 21 (2016) 373e380380of the b-TCP group, and the disaggregative results indicated the
score of “bone regeneration” component of the HAp/Col group was
higher than that of the b-TCP group in contrast to the equivalence
of the “marginal zone” component. Therefore, the higher score of
the HAp/Col group at 4 weeks would owe to these biases by the
differences in sensitivity for detecting newly formed bone. In
addition, the effects of these biases against b-TCP might persist
until the end of the study and lower the results of the b-TCP group
especially in the cases with use of large volume of b-TCP because
of the slower absorption rate of b-TCP. However, at time points
after the observation period of the study such as one year or two
years after surgery, some b-TCP cases showed osteolytic changes of
the implanted sites because of indolent resorption of the b-TCP
remnants. It is therefore possible that in some b-TCP cases, the
remnants were misidentiﬁed as regenerated bone, thereby artiﬁ-
cially increasing the scores in the b-TCP group at the end point of
the study. Furthermore, from a clinical perspective, it was difﬁcult
to distinguish the delayed resorption of the implant remnants
from tumor recurrence. Therefore, the scores of the b-TCP trans-
planted cases at later stages tended to be biased to be both better
and worse. These aspects may represent fundamental limitations
of the scoring system based on x-ray images used in the present
study especially for the b-TCP group, and at the same time, su-
periority of porous HAp/Col in daily clinical practice to evaluate
the bone regeneration at the transplanted site.
The safety assessment revealed a higher incidence of side effects
associated with porous HAp/Col implantation relative to the porous
b-TCP group. The most frequent side effects were wound swelling,
rubor, and increased effusion (9.5%), which were considered to be
associated with a foreign body reaction, allergic reaction to HAp/
Col, infection, or other inﬂammatory response. However, all of the
side effects became asymptomatic during the study period and
never required exenteration of the implant; furthermore, the side
effects did not necessarily degrade the clinical results, although all
cases with side effects were not presented in the results section.
Therefore, serious adverse effects when using porous HAp/Col
should be avoidable in the clinic by careful observation and
appropriate treatment of the implant site.
The present study demonstrated that porous HAp/Col has a
higher capacity for regenerating bone than a currently popular,
gold standard bone substitute. However, most of the bone defects
in the present study were caused by bone tumors or harvesting of
autografts, and we did not evaluate the efﬁcacy of porous HAp/Col
for spinal fusion, bone defects larger than 30 cm3, and osteochon-
dral defects. Therefore, the use of porous HAp/Col should be vali-
dated for such applications.
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